[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642562":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HR+MBC post Alpelisib",null,"Patients with HR+MBC post Alpelisib treatment who are scheduled to receive Everolimus with endocrine therapy, an additional blood sample is collected for biomarker evaluation.",[13,14],"Drug: Everolimus (Afinitor) tablets with endocrine therapy","Procedure: Blood draw for biomarker and genetic analysis",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DRUG","Everolimus (Afinitor) tablets with endocrine therapy","Patients receive standard of care treatment as prescribed by their treating physician. This study only observes the outcomes and does not alter the treatment regimen, dosing, or schedule.\"",[9],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"PROCEDURE","Blood draw for biomarker and genetic analysis","\"A supplementary blood sample is collected from participants to analyze genetic and molecular biomarkers, aiming to identify potential correlations between these markers and clinical response to the standard treatment.\"",[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Breast Cancer coordinator Breast Cancer coordinator","CONTACT","972-03-6974092","hananm@tlvmc.gov.il",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Ichilov-Sourasky Medical Center","RECRUITING","Tel Aviv","Israel","IL",{"type":40,"coordinates":41},"Point",[42,43],34.78057,32.08088,{"lat":43,"lon":42},[46],{"name":47,"role":29,"phone":48,"phoneExt":10,"email":31},"Hanan Mansour Breast cancer study coordinator","97236974062",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100642562","everst--everolimus-after-alpelisib-in-women-with-hormone-receptor-positive-hr-metastatic-breast-cancer-mbc-100642562",false,"NCT07646171","EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)","EVERST- Everolimus After Alpelisib in Women With HR+ MBC- This Phase II, Open-label, Single-arm, Study Investigates the Clinical Benefit of Everolimus Combined With Endocrine Therapy. in Hormone Receptor-positive (HR+), Metastatic Breast Cancer Patients Who Progressed on Prior PI3K Inhibitor Therapy With Endocrine Therapy. The Trial Aims to Determine if Sequential Inhibition of the PI3K\u002FAKT\u002FmTORC1 Pathway Retains Efficacy Post-PI3K Inhibitor Resistance, Hypothesizing That Everolimus Will Demonstrate a Response Rate Exceeding the Historical 9.5% Observed in the BOLERO2 Trial.","MBC","Inclusion Criteria:\n\n* HR+MBC with PI3Kmut Post CDK 4\u002F6+ET Post PI3K inhibitor+ET\n\nExclusion Criteria:\n\n* Women who didn't receive anti-PI3K","ALL","21 Years",{"count":62,"type":63},19,"ESTIMATED","OBSERVATIONAL","This phase II, open-label, single-arm, study investigates the clinical benefit of everolimus combined with endocrine therapy (ET) in hormone receptor-positive (HR+), metastatic breast cancer (MBC) patients who progressed on prior PI3K inhibitor therapy (+ ET). The trial aims to determine if sequential inhibition of the PI3K\u002FAKT\u002FmTORC1 pathway retains efficacy post-PI3K inhibitor resistance, hypothesizing that everolimus will demonstrate a response rate exceeding the historical 9.5% observed in the BOLERO2 trial.",[67],"Hormone Receptor Positive Breast Cancer",[69,70,71],"mTOR inhibitor","Hormone receptor positive breast cancer","PI3K inhibitor","2026-06-09",{"date":74,"type":75},"2026-06-12","ACTUAL",{"date":77,"type":75},"2022-09-01",{"date":79,"type":63},"2027-12-31",{"name":5,"class":6},1]